ObsEva Announces Corporate Updates
July 27, 2022 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...
ObsEva Announces Corporate Updates
July 27, 2022 00:55 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
June 28, 2022 16:01 ET
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
June 17, 2022 07:00 ET
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
June 17, 2022 01:00 ET
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Announces Corporate Updates
May 27, 2022 16:01 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
May 25, 2022 07:00 ET
|
ObsEva SA
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
May 25, 2022 01:00 ET
|
ObsEva SA
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
May 19, 2022 07:05 ET
|
ObsEva SA
GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment...
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022
May 19, 2022 07:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...